



OPTIMIZING PATIENT HEALTH  
BY IMPROVING THE QUALITY  
OF MEDICATION USE

## PQA Specialty Core Measure Set

*Provides standardized, endorsed, meaningful measures to demonstrate  
the positive impact of specialty pharmacy services*

### Treatment of Chronic Hepatitis C: Completion of Therapy

*Percentage of individuals 18 years and older who initiated antiviral therapy during the measurement year for treatment of chronic hepatitis C, and who completed the minimum intended duration of therapy with no significant gap(s) in therapy*

**Use:** Specialty Pharmacy Accreditation programs



Endorsed  
May 2017

### Adherence to Non-Infused Disease Modifying Agents Used to Treat Multiple Sclerosis (PDC-MS)

*Percentage of patients 18 years and older who met the PDC threshold of 80% during the measurement period for medications treating multiple sclerosis*

**Use:** Specialty Pharmacy Accreditation programs



Endorsed  
Dec 2016

### Adherence to Antiretrovirals (PDC-ARV)

*Percentage of patients 18 years and older who met the PDC threshold of 90% during the measurement period for two or more distinct antiretroviral drugs*

**Use:** Medicare Part D Patient Safety Reports; Specialty Pharmacy Accreditation programs



Part D Patient  
Safety  
Reports

### Adherence to Non-Infused Biologic Medications Treating Rheumatoid Arthritis (PDC-RA)

*Percentage of patients 18 years and older with rheumatoid arthritis who met the PDC threshold of 80% during the measurement period for biologic medications used to treat RA*



Endorsed  
May 2018